Sustiva, Efavirenz Newswire

Sustiva, Efavirenz Newswire

Comprehensive Real-Time News Feed for Sustiva, Efavirenz (generic).

Results 1 - 20 of 214 in Sustiva, Efavirenz (generic)

  1. HIV Drug Odefsey Meets Primary Endpoints in Two Phase 3 StudiesRead the original story

    Monday Jul 25 | P&T Community

    Two phase 3b trials evaluating Odefsey for the treatment of patients with human immunodeficiency virus-1 infection have met their primary objectives. The ongoing studies were designed to assess the efficacy and safety of Odefsey in virologically suppressed adults switching from the tenofovir disoproxil fumarate -based regimens Complera or Atripla .

    Comment?

  2. Rwanda: HIV/Aids - How to Break the Bad NewsRead the original story w/Photo

    Sunday Jul 24 | AllAfrica.com

    There are two answers to expect when you take an HIV test - negative or positive. The biggest challenge, however, is how to receive the bad news.

    Comment?

  3. AIDS 2016: SEARCH Study Exceeds 90-90-90 Targets After 2 Years of HIV Test-and-TreatRead the original story w/Photo

    Friday Jul 22 | HIV and Hepatitis

    A large study that embeds "'test-and-treat" for HIV within a larger multi-disease prevention campaign in rural Kenya and Uganda has achieved 82% viral suppression after 2 years, and has already exceeded UNAIDS targets for viral suppression after 1 year of activity, investigators from the SEARCH study reported at the 21st International AIDS Conference this week in Durban. The UNAIDS 90-90-90 targets equate to viral suppression in the entire population of people living with HIV of 73%.

    Comment?

  4. Report: Lifesaving New AIDS Drugs Remain Costly; Older Versions Get CheaperRead the original story

    Friday Jul 22 | Intellectual Property Watch

    The international medical humanitarian organisation MA decins Sans FrontiA res has found that prices of older HIV drugs continue to decline, but newer drugs largely remain expensive. The results were released on 21 July in Untangling the Web , the 18th edition of MSF's report on HIV drug pricing and access, at the International AIDS Conference in Durban.

    Comment?

  5. Gilead's Odefsey Successful in Two Phase IIIb StudiesRead the original story

    Thursday Jul 21 | BioSpace

    Odefsey combines Gilead's emtricitabine and tenofovir alafenamide with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. "Results from these two studies support the efficacy, as well as the renal and bone safety profile, of Odefsey as a new treatment option for virologically suppressed patients."

    Comment?

  6. #AIDS2016: Old drugs may be cheaper, but new ones are out of reachRead the original story w/Photo

    Friday Jul 22 | Iol.co.za

    One thousand volunteers about 200 from around the world have been helping organisers of the 21st International Aids Conference in Durban to make sure the massive gathering runs smoothly. The picture was taken by local cameraman, Abhi Indrarajan, who came to Durban from Sri Lanka 16 years ago to work as a volunteer at the first Aids conference in the city.

    Comment?

  7. Long-acting injectable drugs work well for HIV maintenance therapyRead the original story w/Photo

    Friday Jul 22 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  8. AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance TherapyRead the original story w/Photo

    Thursday Jul 21 | HIV and Hepatitis

    A pair of long-acting injectable antiretrovirals -- cabotegravir and rilpivirine -- administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load, according to 48-week results from the LATTE-2 trial presented at the 21st International AIDS Conference this week in Durban. A related qualitative analysis showed that study participants preferred long-acting injectables over pills for several reasons.

    Comment?

  9. Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection studyRead the original story w/Photo

    Thursday Jul 21 | Aidsmap

    The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus genotypes in HIV/HCV co-infected patients and was safe and well tolerated in the ASTRAL-5 trial, according to results presented yesterday at the 21st International AIDS Conference in Durban, South Africa. A related analysis showed that sofosbuvir/velpatasvir can be safely combined with most widely used antiretrovirals, with the exception of efavirenz.

    Comment?

  10. AIDS 2016: Sofosbuvir/ Velpatasvir Shows High Cure Rate in HIV/HCV Coinfection StudyRead the original story w/Photo

    Thursday Jul 21 | HIV and Hepatitis

    The once-daily coformulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus genotypes and was safe and well tolerated by HIV/HCV coinfected patients in the ASTRAL-5 trial, according to results presented at the 21st International AIDS Conference this week in Durban. A related analysis showed that sofosbuvir/velpatasvir can be safely combined with most widely used antiretrovirals, with the exception of efavirenz.

    Comment?

  11. SEARCH study exceeds 90-90-90 targets after 2 years of `test and treat` for HIV in rural East AfricaRead the original story w/Photo

    Wednesday Jul 20 | Aidsmap

    SEARCH study exceeds 90-90-90 targets after 2 years of `test and treat` for HIV in rural East Africa A large study that embeds `test and treat` for HIV within a larger multi-disease prevention campaign in rural Kenya and Uganda has achieved 82% viral suppression after two years, and already exceeded UNAIDS targets for viral suppression after one year of activity, investigators from the SEARCH study reported today at the 21st International AIDS Conference in Durban, South Africa. The UNAIDS 90-90-90 targets equate to viral suppression in the entire population of people living with HIV of 73%.

    Comment?

  12. Program Raises HIV Viral Suppression Levels in African Communities Above U.N. TargetsRead the original story w/Photo

    Wednesday Jul 20 | POZ

    An intervention has succeeded in raising the rate of HIV diagnosis, treatment and viral suppression in rural Ugandan and Kenyan communities above targets set by the Joint United Nations Programme on HIV and AIDS . Researchers from the SEARCH study, a cluster randomized trial evaluating a test-and-treat intervention in those African communities presented findings at the 21st International AIDS Conference in Durban, South Africa .

    Comment?

  13. ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney SafetyRead the original story w/Photo

    Wednesday Jul 13 | HIV and Hepatitis

    People with HIV who switched from the older tenofovir disoproxil fumarate formulation to tenofovir alafenamide were more likely to maintain viral load suppression and showed improvements in bone density and kidney function biomarkers, according studies presented at the 2016 ASM Microbe conference last month in Boston. Gilead Sciences' tenofovir disoproxil fumarate is one of the most widely used antiretroviral drugs and has been considered generally safe and well-tolerated, but it can cause bone loss soon after starting treatment and lead to kidney problems in susceptible individuals.

    Comment?

  14. It May Be Possible to Take Atripla Just Three Times a WeekRead the original story w/Photo

    Monday Jul 11 | POZ

    People with well controlled HIV who cut back on taking Atripla from daily to three times a week maintained an undetectable viral load for six months, aidsmap reports. Researchers conducted an analysis of 61 HIV-positive people taking once-daily Atripla who had an undetectable viral load for at least two years, had never developed virologic failure and had no known resistance to Atripla's components.

    Comment?

  15. Atripla three times weekly maintains HIV viral suppression for 24 weeksRead the original story w/Photo

    Monday Jul 11 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  16. Switching from tenofovir DF to TAF improves bone and kidney safetyRead the original story w/Photo

    Monday Jul 11 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  17. Is That All There Is to Approval? Folks at the FDA say they know...Read the original story w/Photo

    Saturday Jul 9 | POZ

    Folks at the FDA say they know what's wrong with the fine print when they see it. This ad for DuPont's Sustiva was yanked last year after officials declared that it violated the Federal Food, Drug and Cosmetics Act -- enforceable by law -- with numerous "misleading claims."

    Comment?

  18. Visit our AIDS 2016 webpagesRead the original story w/Photo

    Friday Jul 8 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  19. Sunil Parikh (right) with Ugandan research colleagues. The team...Read the original story

    Thursday Jul 7 | PressReleasePoint

    The overlapping disease burdens of HIV and malaria in sub-Saharan Africa continue to pose an enormous health threat to millions of people, many of whom are children. While antiretroviral therapy regimens are increasingly being used to effectively suppress HIV, these same drugs can dramatically change the effectiveness of an antimalarial therapy for patients who are being simultaneously treated for both diseases.

    Comment?

  20. HIV treatment interferes with malaria medsRead the original story

    Thursday Jul 7 | Science Blog

    The overlapping disease burdens of HIV and malaria in sub-Saharan Africa continue to pose an enormous health threat to millions of people, many of whom are children. While antiretroviral therapy regimens are increasingly being used to effectively suppress HIV, these same drugs can dramatically change the effectiveness of an antimalarial therapy for patients who are being simultaneously treated for both diseases.

    Comment?